DE69841279D1 - Verwendung von humanem Parathyroid-hormon - Google Patents

Verwendung von humanem Parathyroid-hormon

Info

Publication number
DE69841279D1
DE69841279D1 DE69841279T DE69841279T DE69841279D1 DE 69841279 D1 DE69841279 D1 DE 69841279D1 DE 69841279 T DE69841279 T DE 69841279T DE 69841279 T DE69841279 T DE 69841279T DE 69841279 D1 DE69841279 D1 DE 69841279D1
Authority
DE
Germany
Prior art keywords
parathyroid hormone
human parathyroid
human
osteoporosis
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841279T
Other languages
German (de)
English (en)
Inventor
John Dietrich
Sverker Ljunghall
Sven Sjoegren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shire NPS Pharmaceuticals Inc
Original Assignee
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NPS Pharmaceuticals Inc filed Critical NPS Pharmaceuticals Inc
Application granted granted Critical
Publication of DE69841279D1 publication Critical patent/DE69841279D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69841279T 1997-06-19 1998-06-08 Verwendung von humanem Parathyroid-hormon Expired - Lifetime DE69841279D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702401A SE9702401D0 (sv) 1997-06-19 1997-06-19 Pharmaceutical use

Publications (1)

Publication Number Publication Date
DE69841279D1 true DE69841279D1 (de) 2009-12-17

Family

ID=20407482

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69841279T Expired - Lifetime DE69841279D1 (de) 1997-06-19 1998-06-08 Verwendung von humanem Parathyroid-hormon
DE69826132T Expired - Lifetime DE69826132T2 (de) 1997-06-19 1998-06-08 Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69826132T Expired - Lifetime DE69826132T2 (de) 1997-06-19 1998-06-08 Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption

Country Status (14)

Country Link
US (8) US6284730B1 (https=)
EP (2) EP1001802B1 (https=)
JP (3) JP4989811B2 (https=)
AT (2) ATE447410T1 (https=)
AU (1) AU753477B2 (https=)
CA (2) CA2294101C (https=)
CY (1) CY1110287T1 (https=)
DE (2) DE69841279D1 (https=)
DK (2) DK1001802T3 (https=)
ES (2) ES2335404T3 (https=)
PT (2) PT1001802E (https=)
SE (1) SE9702401D0 (https=)
WO (1) WO1998057656A1 (https=)
ZA (1) ZA984947B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
ES2394211T3 (es) 2000-06-20 2013-01-23 Novartis Ag Procedimiento de administración de bifosfonatos
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
PL211976B1 (pl) 2001-06-01 2012-07-31 Novartis Ag Kompozycja farmaceutyczna do podawania doustnego oraz zastosowanie kompozycji
US6827250B2 (en) * 2001-06-28 2004-12-07 Microchips, Inc. Methods for hermetically sealing microchip reservoir devices
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004022033A1 (en) * 2002-09-04 2004-03-18 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
US20050119183A1 (en) * 2003-11-12 2005-06-02 Nps Allelix Corp. Method for treating bone loss using parathyroid hormone
CA2595457A1 (en) 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
EP1896134A2 (en) 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
PL1734251T3 (pl) * 2005-06-17 2007-05-31 Magneti Marelli Powertrain Spa Wtryskiwacz paliwa
CN101355959B (zh) * 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
WO2010115932A1 (en) * 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
ES2662018T3 (es) * 2009-09-09 2018-04-05 Asahi Kasei Pharma Corporation Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades
EP2509996A1 (en) 2009-12-07 2012-10-17 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
ES2831699T3 (es) 2011-12-13 2021-06-09 Amorphical Ltd Un carbonato de calcio morfo para el tratamiento de la mala absorción de calcio y los trastornos metabólicos óseos
CA2977812A1 (en) * 2015-03-03 2016-09-09 Radius Health, Inc. Uses of pthrp analogue in reducing fracture risk
US10758565B2 (en) 2015-06-04 2020-09-01 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
AU2017349921B2 (en) 2016-10-25 2023-06-15 Amorphical Ltd Amorphous calcium carbonate for treating a leukemia
KR102327010B1 (ko) * 2019-03-29 2021-11-16 서울대학교병원 재조합 부갑상선 호르몬을 포함하는 회전근 개 봉합 후 치유용 조성물
KR20220038056A (ko) 2019-07-23 2022-03-25 아모피컬 리미티드 운동 수행능력을 개선시키기 위한 비정질 탄산칼슘

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3768177A (en) 1972-08-02 1973-10-30 R Thomas Educational device
US3886132A (en) 1972-12-21 1975-05-27 Us Health Human parathyroid hormone
US4468464A (en) 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US4105602A (en) 1975-02-10 1978-08-08 Armour Pharmaceutical Company Synthesis of peptides with parathyroid hormone activity
US4016314A (en) 1975-06-26 1977-04-05 Hallco Inc. Embroidered fruit bowl wall hanging and kit for making same
US4264731A (en) 1977-05-27 1981-04-28 The Regents Of The University Of California DNA Joining method
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4199060A (en) 1978-07-20 1980-04-22 Howard Hardware Products, Inc. Lock installation kit
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
US4383066A (en) 1980-04-15 1983-05-10 Mitsubishi Gas Chemical Company, Inc. Polyphenylene ether resin composition
JPS5825439B2 (ja) 1980-12-30 1983-05-27 株式会社林原生物化学研究所 ヒト副甲状腺ホルモンの製造方法
US4394443A (en) 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4624926A (en) 1981-01-02 1986-11-25 The Research Foundation Of State University Of New York Novel cloning vehicles for polypeptide expression in microbial hosts
NO163060C (no) 1981-03-13 1990-03-28 Damon Biotech Inc Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer.
US4385212A (en) 1981-10-05 1983-05-24 Bell Telephone Laboratories Incorporated Expandable communication terminal housing
US4424278A (en) 1981-11-16 1984-01-03 Research Corporation Cancer detection procedure using an acyl carrier protein
US4532207A (en) 1982-03-19 1985-07-30 G. D. Searle & Co. Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4595658A (en) 1982-09-13 1986-06-17 The Rockefeller University Method for facilitating externalization of proteins synthesized in bacteria
WO1984001173A1 (en) 1982-09-15 1984-03-29 Immuno Nuclear Corp Production of mature proteins in transformed yeast
DE3312928A1 (de) 1983-04-11 1984-11-22 Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig Human-parathormon produzierende hybridvektoren und human-parathormongen
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4588684A (en) 1983-04-26 1986-05-13 Chiron Corporation a-Factor and its processing signals
US4637980A (en) 1983-08-09 1987-01-20 Smithkline Beckman Corporation Externalization of products of bacteria
CA1213537A (en) 1984-05-01 1986-11-04 Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee Polypeptide expression method
ATE78515T1 (de) 1984-10-05 1992-08-15 Genentech Inc Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung.
JPS61267528A (ja) 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
IL77227A (en) 1984-12-06 1992-08-18 Synergen Biolog Inc Recombinant methods for production of serine protease inhibitors and methods for isolation of same
US4812311A (en) 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
IL78342A (en) 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4994559A (en) 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IE67035B1 (en) 1986-07-08 1996-02-21 Genetics Inst Production and use of non-glycosylated IL-6
US5010010A (en) 1986-10-22 1991-04-23 Selmer-Sande, A.S. Production of human parathyroid hormone from microorganisms
US5420242A (en) 1986-10-22 1995-05-30 Kaare M. Gautvik Production of human parathyroid hormone from microorganisms
WO1988003171A1 (en) 1986-10-30 1988-05-05 Synergen Biologicals, Inc. Human pancreatic secretory trypsin inhibitors produced by recombinant dna methods and processes for the production of same
FI77278C (fi) 1986-10-31 1989-02-10 Ahlstroem Oy Foerfarande och anordning foer foerbraenning av sodasvartlut.
US4833125A (en) 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
FR2618914B1 (fr) 1987-07-31 1991-12-06 Alain Souloumiac Perfectionnements apportes aux interrupteurs optomagnetiques
US5059587A (en) 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
IL88344A (en) 1987-11-12 1994-06-24 Schering Corp Accelerating bone formation using a factor that accelerates colonies of granulocyte macrophages
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5223407A (en) 1988-08-31 1993-06-29 Allelix Inc. Excretion of heterologous proteins from e. coli
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5171670A (en) 1989-05-12 1992-12-15 The General Hospital Corporation Recombinant dna method for production of parathyroid hormone
USRE37919E1 (en) 1989-05-12 2002-12-03 The General Hospital Corporation Recombinant DNA method for production of parathyroid hormone
DE3935738A1 (de) 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
GB9020544D0 (en) 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
WO1992009304A1 (en) * 1990-11-26 1992-06-11 Recker Robert R Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth)
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
AU3095092A (en) * 1991-12-09 1993-07-19 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
JPH07502507A (ja) 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
IT1255723B (it) 1992-10-09 1995-11-13 Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
TW303299B (https=) 1993-07-22 1997-04-21 Lilly Co Eli
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
WO1996007417A1 (en) * 1994-09-09 1996-03-14 The Procter & Gamble Company Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
AU3674895A (en) 1994-09-09 1996-03-27 Procter & Gamble Company, The Estrogens and parathyroid hormone for treating osteoporosis
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
US5550134A (en) 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
US5599822A (en) 1995-06-06 1997-02-04 Eli Lilly And Company Methods for minimizing bone loss
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US5945412A (en) 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use

Also Published As

Publication number Publication date
US20120148684A1 (en) 2012-06-14
ATE447410T1 (de) 2009-11-15
CA2698626A1 (en) 1998-12-23
DE69826132D1 (de) 2004-10-14
JP2014015479A (ja) 2014-01-30
EP1473040B1 (en) 2009-11-04
ATE275419T1 (de) 2004-09-15
JP4989811B2 (ja) 2012-08-01
DE69826132T2 (de) 2005-09-15
US20030162716A1 (en) 2003-08-28
JP2010100644A (ja) 2010-05-06
AU753477B2 (en) 2002-10-17
US20110071081A1 (en) 2011-03-24
US7507715B2 (en) 2009-03-24
ZA984947B (en) 1999-01-04
DK1473040T3 (da) 2010-03-15
US8765674B2 (en) 2014-07-01
CA2294101C (en) 2010-08-03
ES2335404T3 (es) 2010-03-26
DK1001802T3 (da) 2005-01-17
HK1029738A1 (en) 2001-04-12
JP2002504140A (ja) 2002-02-05
CA2294101A1 (en) 1998-12-23
US8153588B2 (en) 2012-04-10
US7749543B2 (en) 2010-07-06
CA2698626C (en) 2016-02-09
US20060211613A1 (en) 2006-09-21
PT1001802E (pt) 2005-01-31
EP1001802B1 (en) 2004-09-08
JP5525825B2 (ja) 2014-06-18
SE9702401D0 (sv) 1997-06-19
US6284730B1 (en) 2001-09-04
PT1473040E (pt) 2010-02-02
US20090118192A1 (en) 2009-05-07
EP1473040A1 (en) 2004-11-03
WO1998057656A1 (en) 1998-12-23
US20140256632A1 (en) 2014-09-11
HK1070816A1 (en) 2005-06-30
US7018982B2 (en) 2006-03-28
EP1001802A1 (en) 2000-05-24
CY1110287T1 (el) 2015-01-14
AU7945898A (en) 1999-01-04
US20020002135A1 (en) 2002-01-03
ES2229511T3 (es) 2005-04-16

Similar Documents

Publication Publication Date Title
CY1110287T1 (el) Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
ATE104854T1 (de) Pharmazeutische zusammensetzung zur behandlung von osteoporose.
EP0552256A4 (https=)
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
EA200000748A1 (ru) Способ введения мономерных аналогов инсулина
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
GB8927546D0 (en) Process for the production of biologically active tgf-beta
ATE481970T1 (de) Zusammensetzungen enthaltend capsaicin oder capsaicin analoge und ein anästhetikum
BR9402902A (pt) Hormônio paratiróideo e raloxifeno, compostos e formulação farmacêutica.
NO20101190L (no) Anvendelse av buprenorfin i fremstillingen av et medikament
FI932385A0 (fi) Behandling av osteoporos genom anvaendning av somatoliberin (GRF) i en kombination med paratyreoideahormon (PTH)
AU1255002A (en) Delayed-release pharmaceutical formulations
ATE100320T1 (de) Verwendung von thromboxan-a2-rezeptorantagonisten zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von hautkrankheiten.
DK0629400T3 (da) Idebenon-holdige præparater til behandling af Alzheimer's syge
AU7426487A (en) Method of treating depression using d-fenfluramine
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
ATE311897T1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
GB2260702B (en) Improvements relating to the treatment of haemophilia B by subcutaneous injection of factor 1X
DE69927599D1 (de) Verwendung von wachstumshormon und analoga davon für die behandlung von säugern mit familiärer hypercholesterolämie
UA10248A (uk) Спосіб лікування ішемічної хвороби серця на фоні цукрового діабету

Legal Events

Date Code Title Description
8380 Miscellaneous part iii

Free format text: DINGLICHES RECHT WURDE BESTELLT

8364 No opposition during term of opposition